Rahul Aggarwal
Clinical trials sponsored by Rahul Aggarwal, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New imaging agent could reveal which cancers respond to immunotherapy Results expected Dec 2026 (estimated)
- New drug combo targets CD46 in aggressive prostate cancer Results expected Jul 2027 (estimated)
-
New drug combo targets CD46 in aggressive prostate cancer
Disease control OngoingResearchers are testing a new drug called FOR46, which seeks out a protein called CD46 on cancer cells, together with enzalutamide, a standard hormone therapy, in men whose prostate cancer has spread and worsened despite prior treatment with abiraterone. The trial aims to find th…
Phase 1/2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a three-drug cocktail outsmart resistant prostate cancer?
Disease control OngoingThis phase 2 trial is testing whether combining three drugs—ZEN-3694, enzalutamide, and pembrolizumab—can shrink tumors or lower PSA levels in men with metastatic castration-resistant prostate cancer that has worsened despite prior treatment. ZEN-3694 blocks a protein that fuels …
Phase 2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug cocktail shows promise against Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…
Phase 2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC